Recent News

Early Results of Phase I Study of CAR T-Cell Therapy in Multiple Myeloma

Novel Four-Drug Combination Therapy for Newly Diagnosed Multiple Myeloma

First-in-Class Agent Targets NF-kB Signaling in Multiple Myeloma

Venetoclax Combination Therapy for Resistant Multiple Myeloma

ASH 2018: First-Line Combination Regimens in Transplant-Ineligible Patients With Myeloma

ASH 2018: Novel Agent for Resistant Multiple Myeloma Under Study

ASH 2018: Is Urine Immunofixation Necessary to Define Complete Remission in Myeloma

ASH 2018: Frailty-Adjusted Treatment Approach for Elderly Patients With Myeloma

ASH 2018: Ixazomib Maintenance After Transplantation in Newly Diagnosed Multiple Myeloma

ASH 2018: Double vs. Single Autologous Transplantation in Newly Diagnosed Myeloma

ASH 2018: Daratumumab Combination Therapy in Newly Diagnosed Multiple Myeloma

ASH 2018: Transplant Versus Continuous Lenalidomide-Based Therapy for Relapsed Multiple Myeloma

Myeloma Crowd Launches Free Online Resource for Patients With Multiple Myeloma

FDA Grants Regenerative Medicine Advanced Therapy Designation to CAR T-Cell Therapy

ESMO 2018: Adding Liposomal Doxorubicin to Standard First-Line Therapy in Multiple Myeloma

FDA Grants Priority Review to Ruxolitinib for Acute Graft-Versus-Host-Disease

ASTRO 2018: Impact of Dosage on Re-irradiation Rates in Multiple Myeloma

FDA Approves Immunotherapy Combination in Relapsed or Refractory Multiple Myeloma

Rare Case of CML After Stem Cell Transplantation in Patient With Multiple Myeloma

Phase I Study of New Triplet Therapy for Resistant Myeloma

FDA Offers Draft Guidance on Use of MRD in Hematologic Malignancies

Investigational Therapy for Myeloma, STRO-001, Granted Orphan Drug Designation by FDA

ESMO 2018: Strategy for Offsetting Lenalidomide-Induced Rash in Multiple Myeloma

FDA Grants Priority Review to Selinexor for Pentarefractory Multiple Myeloma

Can Simple Blood Tests Diagnose Early Multiple Myeloma?

FDA Permits Use of Next-Generation Sequencing–Based Test in Multiple Myeloma

Quality Care Symposium: Steady Improvement in Survival in Multiple Myeloma

FDA Approves Once-Weekly Carfilzomib With Dexamethasone in Resistant Multiple Myeloma

Novel Approach to Restoring Beneficial Gut Bacteria After HCT

Can Artificial Intelligence Platform Optimize Combination Therapy for Multiple Myeloma?

High-Risk Subset of Newly Diagnosed Multiple Myeloma Identified

Is Resilience a Protective Factor in Disease Trajectory of Multiple Myeloma?

Former MLB Sluggers Team up to Create Awareness of Multiple Myeloma

Monoclonal Antibodies in Multiple Myeloma: Focus on Infusion-Related Reactions

ALL After Multiple Myeloma: Clonally Related or Not?

FDA Accepts Supplemental Biologics License Application for Triplet Myeloma Therapy

Accuracy of Blood Versus Urine Assays in Diagnosis of Multiple Myeloma

Potential of bb2121 CAR T-Cell Therapy in Resistant Multiple Myeloma

UAB Leads Recruitment for Novel Clinical Trial in Multiple Myeloma

Phase III ADMYRE Trial: Plitidepsin + Dexamethasone in Resistant Myeloma

FDA Issues Warning About Long-Term Use of Azithromycin After Donor Stem Cell Transplant

Pembrolizumab in Combination Therapy for Resistant Multiple Myeloma

FDA Grants Orphan Drug Designation to Human Antibody for Treatment of Multiple Myeloma

FDA Grants Fast Track Designation to Galinpepimut-S for Treatment of Myeloma

Preliminary Safety Results of Triplet Therapy for Multiple Myeloma Reported